Press Releases
Teva Announces Favorable Court Ruling in Generic Hyzaar® and Cozaar® LitigationJerusalem, March 2, 2010
Copaxone® 15-Year Study in Multiple Sclerosis Patients Demonstrates Robust Long-Term Efficacy and Safety
Jerusalem, Israel, February 25, 2010
Teva To Present At The 14th Annual Israeli Equities Conference
Jersulaem, Israel, February 22, 2010
Teva Reports Record Full Year 2009 And Fourth Quarter Results
Jerusalem, Israel, February 16, 2010
Teva Announces Agreement on Famvir® Patent Challenge
Jerusalem, February 15, 2010
Eli Hurvitz Takes a Three Week Medical Leave of Absence
Jerusalem, Israel, February 14, 2010
Teva Acquires Marketing Rights For Oral Laquinimod In The Nordic And Baltic Regions
Jerusalem, Israel, Lund, Sweden, February 8, 2010
Teva Announces Settlement in Principle regarding Certain Drug Pricing Lawsuits
Jerusalem, February 5, 2010
Teva Announces FDA Accepts BLA for XM02
Jerusalem, February 2, 2010
Teva Receives Favorable Court Decision Regarding Generic Temodar®
Jerusalem, Israel, January 26, 2010
Court of Appeals Affirms Favorable Decision Regarding Generic Prevacid® SoluTab
Jerusalem, Israel, January 22, 2010
Teva Announces Tentative Approval of Generic Femara® Tablets
Jerusalem, Israel, January 21, 2010
Teva to Donate Medicine to Haiti Earthquake Relief Effort
Jerusalem, Israel, January 19, 2010
Teva to Report Fourth Quarter and Full Year 2009 Financial Results on February 16, 2010
Jerusalem, Israel, January 19, 2010
Moody's Upgrades Teva Rating to A3
Jerusalem, Israel, January 14, 2010
Teva To Present At The 28th Annual J.P. Morgan Healthcare Conference
Jerusalem, Israel, January 8, 2010
Teva Presents Strategic Plan to Deliver Strong Growth
Jerusalem, Israel, January 7, 2010
Teva Announces Settlement Agreements With AstraZeneca Regarding Generic Prilosec® and Nexium®
Jerusalem, Israel, January 7, 2010
Teva to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference
Jerusalem, Israel, January 4, 2010
Teva Invites Public to Listen to Analyst Meeting Webcast
Jerusalem, Israel, December 29, 2009
Teva-KOWA Pharma to Acquire a Majority Share Interest in Taisho Pharmaceutical Industries
Jerusalem, Israel, December 24, 2009
Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications
Jerusalem, Israel, Bothell, WA and Vancouver, Canada, December 21, 2009
FDA Approves Newly Revised Prescribing Information For Azilect® Reducing Medication And Food Restrictions
Jersulam, Israel, December 14, 2009
Teva Announces The Submission Of A Biologics License Application (BLA) For XM02 For The Treatment Of Chemotherapy-Induced Neutropenia
Jersualem, Israel, December 1, 2009
Teva to Present at The Credit Suisse 18th Annual Healthcare Conference
Jerusalem, Israel, November 11, 2009
Teva Receives Final Approval For Generic Prevacid® Delayed-Release Capsules
Jerusalem, Israel, November 10, 2009
Teva Receives Favorable Court Decision Regarding Generic Prevacid® Solutab
Jerusalem, Israel, November 10, 2009
Teva Files Amended Complaint Against Monenta/Sandoz to Include Infringement of Three Copaxone®-Related Patents
Jerusalem, Israel, November 10, 2009
Teva Introduces Fexofenadine HCL and Pseudoephedrine HCL Extended-Release Tablets; An Alternative to Allegra-D® 12 Hour Tablets
Jerusalem, Israel, November 3, 2009
Teva Reports Third Quarter 2009 Results
Jerusalem, Israel, November 3, 2009
Teva Comments on Positive Results of Phase III Trial in Mediwound's Debrase®
Jerusalem, Israel, October 20, 2009
Teva Comments on Mylan Paragraph IV Filing for Copaxone®; Files Lawsuit Against Generic Filer for Patent Infringement
Jerusalem, Israel, October 16, 2009
Teva to Report Third Quarter 2009 Financial Results on November 3, 2009
Jerusalem, Israel, October 15, 2009
Teva Provides Update on Generic Seroquel® Litigation
Jerusalem, Israel, September 25, 2009
Teva Provides Update on Generic Evista® Litigation
Jerusalem, Israel, September 24, 2009
Results of ADAGIO Study with AZILECT® in Parkinson's Disease Published in New England Journal of Medicine
Jerusalem, Israel, September 23, 2009
Teva to Present at the UBS Global Life Sciences Conference
Jerusalem, Israel, September 17, 2009
Teva Announces Presentations at Bank Conferences
Jerusalem, Israel, September 11, 2009
Copaxone® Significantly Reduced Disease Severity in Long-Term Treated Multiple Sclerosis Patients
Jerusalem, Israel, September 10, 2009
New Data Highlights Advances in MS Treatment Research
Jerusalem, September 8, 2009
Teva Provides Update On Generic Singulair® Litigation
Jerusalem, Israel, August 19, 2009
Teva Announces Approval And Launch of Oxaliplatin Injection
Jerusalem, Israel, August 11, 2009
Teva Announces Appeals Court Ruling Affirming Invalidation Of Yasmin® Patent
Jerusalem, Israel, August 5, 2009
Teva Reports Second Quarter 2009 Results
Jerusalem, Israel, July 28, 2009
Teva And Ortho-McNeil-Janssen Settle Ortho Tri-Cyclen®Lo Litigation
Jerusalem, Israel, July 24, 2009
Teva Provides Update On Generic Ortho Tri-Cyclen®Lo
Jerusalem, Israel, July 17, 2009
FDA Approves Plan B® One-Step, a New One-Pill Emergency Contraceptive
Jerusalem, Israel, July 13, 2009
Teva Provides Update On Generic Ortho Tri-Cyclen® Lo
Jerusalem, Israel, July 7, 2009
Teva Announces Approval and Launch of Tri-Lo Sprintec Tablets
Jerusalem, Israel, July 1, 2009
Teva and Antares Announce FDA Approval of Needle-Free Injector Product for Administration of Tev-Tropin® (Human Growth Hormone)
Jerusalem, Israel and Ewing, New Jersey, June 30, 2009
Court Grants Teva Summary Judgment Of Non-Infringement On Eloxatin®
Jerusalem, Israel, June 18, 2009
Teva to Present at the Goldman Sachs 30th Annual Global Healthcare Conference
Jerusalem, Israel, June 9, 2009
Teva to Present at the Sanford C. Bernstein & Co., LLC Twenty-Fifth Annual Strategic Decision Conference 2009
Jerusalem, Israel, May 25, 2009
Federal Circuit Affirms Denial of Preliminary Injunction Regarding Teva's Generic Protonix® Tablets
Jerusalem, Israel, May 14, 2009
Lonza and Teva Announce Receipt of Regulatory Approval
Jerusalem, Israel and Basel, Switzerland, May 14, 2009
Teva Announces Approval And Launch Of Generic Urso 250® And Urso Forte®
Jerusalem, Israel, May 14, 2009
Teva Provides Update On Generic Actonel® Litigation
Jerusalem, Israel, May 13, 2009
Teva Announces Presentations At Bank Conferences
Jerusalem, Israel, May 13, 2009
Teva Announces Extension of Patent Protection for Azilect®
Jerusalem, Israel, May 6, 2009
Teva reports First Quarter 2009 Results
Jerusalem, Israel, May 5, 2009
New Data Illustrate Novel Mechanism of Action of Laquinimod, An Oral Compound For The Treatment of Multiple Sclerosis
Jerusalem, Israel, Lund, Sweden and Seattle, Washington, April 28, 2009
Long-Term Study with COPAXONE® Indicated Protective Effect on Brain Tissue in Multiple Sclerosis Patients
Jerusalem, Israel, April 28, 2009
Teva Comments on Generic Evista® Preliminary Injunction
Jerusalem, Israel, April 23, 2009
Teva to Present New Data on its Innovative Therapies for Multiple Sclerosis and Parkinson's Disease at the Upcoming 2009 American Academy of Neurology Annual Meeting
Jerusalem, Israel, April 22, 2009
Teva to Report First Quarter 2009 Financial Results on May 5, 2009
Jerusalem, Israel, April 20, 2009
Teva Introduces First Generic Adderall XR® Capsules in the United States
Jerusalem, Israel, April 2, 2009
Teva Announces Approval of Generic Yaz® Tablets
Jerusalem, Israel, April 1, 2009
Teva Announces Approval and Launch of Generic Topamax® Tablets
Jerusalem, Israel, March 27, 2009
Teva Announces FDA Response to Citizen Petition
Jerusalem, Israel, March 25, 2009
Teva and Medicis Announce Settlement Agreement
Jerusalem, Israel and Scottsdale, Arizona, March 19, 2009
Teva Announces Approval and Launch of Generic Solodyn® Extended-Release Tablets
Jerusalem, Israel, March 18, 2009
Study Demonstrates that Qvar® is More Likely to Achieve Successful Asthma Control with Less Exacerbations
Jerusalem, Israel, March 17, 2009
Teva to Present at the Cowen and Company 29th Annual Healthcare Conference
Jerusalem, Israel, March 16, 2009
Teva to Present at the Barclays Capital Global Healthcare Conference
Jerusalem, Israel, March 11, 2009
Copaxone® Approved by the FDA for Patients with a First Clinical Event Suggestive of Multiple Sclerosis
Jerusalem, Israel, March 3, 2009
Teva Provides 2009 Financial Outlook
Jerusalem, Israel, February 17, 2009
Teva Reports Record Full Year 2008 and Fourth Quarter Results
Jerusalem, Israel, February 17, 2009
Oral Laquinimod for Multiple Sclerosis Granted Fast Track Status by FDA
Jerusalem, Israel and Lund, Sweden, February 12, 2009
Teva Announces Approval and Launch of Generic Imitrex® Tablets
Jerusalem, Israel, February 11, 2009
Copaxone® is Approved for Treatment of Patients with a First Clinical Event Suggestive of Multiple Sclerosis
Jerusalem, Israel, February 4, 2009
Teva Announces Approval of Generic Risperdal ® Oral Solution
Jerusalem, Israel, January 30, 2009
Teva to Report Fourth Quarter and Full Year 2008 Financial Results on February 17, 2009
Jerusalem, Israel, January 27, 2009
Teva and Lonza Announce Strategic Partnership to Become a Leading Global Provider of Biosimilars
Jerusalem, Israel, and Basel, Switzerland, January 20, 2009
Teva to Present at the 27th Annual J.P. Morgan Healthcare Conference
Jerusalem, Israel, January 8, 2009
Teva to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference
Jerusalem, Israel, January 7, 2009
Teva Announces Amir Elstein Joins Board of Directors
Jerusalem, Israel, January 5, 2009
Archive: 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999
| Legal Note | Site Map | Copyright © 1999 - 2010 Teva. All rights reserved |